

## Special Issue

# Gene Delivery and Gene Editing

### Message from the Guest Editor

While gene delivery and editing technologies have become commonplace due to the prevalence of highly advanced methods, it is essential to recognize that ongoing development is imperative. The ultimate role of genetic engineers is to acquire a flawless technology that can, in a specific and efficient manner, revert mutated or defective genes to their healthy wild-type form without any side effects. In this Special Issue, we aim to compile reviews addressing the current status, challenges, and issues related to gene editing, gene delivery technologies, and peripheral technologies in drug development, diagnostics, and medicine. We also expect comprehensive articles that present new insights from diverse perspectives. We are particularly interested in exploring the potential of new functional modules for CRISPR-Cas, proteins beyond typical Cas proteins, advancements in TALEN, the discovery and characterization of unknown type I or II transposons and viruses, and the medical applications stemming from these discoveries.

- gene delivery
- gene editing
- novel module
- transposon
- genetic engineering

---

### Guest Editor

Dr. Kosuke Ishikawa

Global Consolidated Research Institute for Science Wisdom,  
Comprehensive Research Organization, Waseda University, Tokyo 162-0041, Japan

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/192901](https://mdpi.com/si/192901)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).